Human Growth Hormone Research Paper

Human Growth Hormone Research Paper-5
Moore, MD, a pediatric endocrinologist at Children’s Mercy Hospital, Kansas City, Mo., presented the data at the annual meeting of the Endocrine Society.“Despite the fact that human growth hormone is a proven treatment for growth hormone deficiency, daily use of our current formulations can be a factor that affects compliance,” said Dr. He cited a 2008 Misperceptions about the consequences of missed doses and discomfort with injections were strongly associated with noncompliance, the authors of that paper noted.Last year, the Growth Hormone Research Society a consensus paper calling for more research into longer-acting formulations (Eur J Endocrinol. The group of 55 international experts described several strategies for creating long-acting growth hormone formulations, including depot formulations, pegylation, prodrugs, noncovalent albumin binding growth hormone compounds, and growth hormone fusion proteins.Cohort B comprised six men and women younger than 35 years, who took 0.8 mg/kg per month.

They all had been diagnosed with adult-onset growth hormone deficiency, but had stable pituitary function.Access to society journal content varies across our titles.If you have access to a journal via a society or association membership, please browse to your society journal, select an article to view, and follow the instructions in this box.Within the first year, all children taking the 3.5-mg/kg dose had achieved normal IGF-1 levels, which were consistent with levels achieved in the ANSWER dataset of somatropin (r DNA origin) injection (Norditropin) recombinant human growth hormone (Clin Epidemiol. Height velocity improved, as did height standard deviation.By year 3, patients were a mean of 1.25 SDs below expected height – a significant improvement over baseline.All subjects received one injection per month for 5 months.Cohort A comprised 21 men and women aged 35 years or older, who took 0.6 mg/kg per month.The first 12 months of the study consisted of dose-ranging trials, with initial doses of 5 mg/kg each month, then 2.5 mg/kg twice a month, and then 1.15 mg/kg weekly.During the last 2 years of the study, all children were taking 3.5 mg/kg, once a month.Other adverse events were headache, extremity pain, arthralgia, and musculoskeletal pain.Although the numbers were small overall, reports did increase after all the children were switched to the 3.5-mg/kg dose.


Comments Human Growth Hormone Research Paper

The Latest from ©